Investing in Acorda Therapeutics, Inc. (ACOR)

Valuation methodValue, $Upside, %
Artificial intelligence (AI)16.111093
Intrinsic value (DCF)16.111093
Graham-Dodd Method0.00-100
Graham Formula585.8543296

Company description

Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its products include Inbrija (levodopa inhalation powder), Ampyra (dalfampridine), Fampyra (fampridine), and Selincro (nalmefene). The firm's also offers Research and Development Programs like ARCUS for acute migraine, Cimaglermin alfa, and rHIgM22. The company was founded by Ronald Cohen in 1995 and is headquartered in New York, NY.